Related Experiment Videos
Amiodarone and pulmonary fibrosis
European Journal of Clinical Pharmacology
|January 1, 1983
Summary
Amiodarone may cause pulmonary fibrosis. This study found a link between amiodarone use and lung disease in patients, suggesting a hypersensitivity reaction may be involved.
Area of Science:
- Pulmonology
- Cardiology
- Pharmacology
Background:
- Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatment options.
- Amiodarone is an antiarrhythmic drug commonly used for cardiac arrhythmias.
- Potential drug-induced lung injury is a concern with amiodarone therapy.
Purpose of the Study:
- To investigate a potential causal relationship between amiodarone administration and the development of pulmonary fibrosis.
- To explore the incidence and characteristics of amiodarone-induced pulmonary fibrosis.
Main Methods:
- Retrospective review of 25 cases of idiopathic pulmonary fibrosis confirmed by open chest lung biopsy.
- Analysis of patient history, including amiodarone dosage, duration of use, and exclusion of other potential causative factors.
- Literature review of additional cases to support findings.
Main Results:
- Five out of 25 patients with IPF had taken amiodarone (less than 600 mg daily) for 1-6 years.
- No prior lung disease was noted before amiodarone initiation; other IPF causes were excluded.
- Two patients died from respiratory insufficiency, and one still suffers from serious sequelae.
Conclusions:
- A causal link between amiodarone and pulmonary fibrosis is suggested.
- The findings indicate a potential hypersensitivity mechanism underlying amiodarone-induced lung injury.
- Clinicians should be vigilant for pulmonary complications in patients treated with amiodarone.